Clinical Report: Results of a Third Round of Salvage Spine Stereotactic Radiosurgery
Overview
This report presents outcomes from a case series of six patients who underwent a third course of salvage spine stereotactic radiosurgery (sSRS) for spinal metastases. The findings indicate that repeat sSRS can achieve durable local control with manageable toxicity, despite the risks associated with re-irradiation.
Background
Spine stereotactic radiosurgery (sSRS) is a targeted treatment for spinal metastases that allows for high-dose radiation delivery while minimizing damage to surrounding healthy tissue. As patients with spinal metastases often experience disease progression, understanding the efficacy and safety of repeated sSRS is crucial for optimizing treatment strategies. This study addresses a gap in the literature regarding the outcomes of multiple sSRS courses in patients with prior radiographic progression.
Data Highlights
Patient
Number of sSRS Courses
Radiographic Failure Rate
1
3
30%
2
3
20%
3
3
40%
4
3
10%
5
3
50%
6
3
20%
Key Findings
Six patients received a total of 10 sSRS treatments across three courses.
The overall radiographic failure rate after the third sSRS course was 30%.
Low rates of radiation-induced vertebral compression fractures (VCF) were observed.
Incidence of radiation myelopathy was minimal, with no new neurological deficits reported.
Pain flare requiring corticosteroids occurred in 40% of patients post-treatment.
Cumulative dose constraints were adhered to, mitigating risks to critical neural structures.
Clinical Implications
The findings suggest that repeat sSRS can be a viable option for patients with spinal metastases experiencing progression after initial treatments. Clinicians should consider the potential for durable local control while carefully monitoring for toxicity, particularly pain flares and vertebral fractures.
Conclusion
This case series supports the use of a third course of salvage sSRS in selected patients, highlighting its potential for effective management of spinal metastases with acceptable safety profiles.
